The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Pfizer Inc

NYSE: PFE
Last

(U.S.) $29.03

Today's change+0.03 +0.10%
Updated February 5 4:02 PM EST. Delayed by at least 15 minutes.
 

Pfizer Inc

NYSE: PFE
Last

(U.S.) $29.03

Today's change+0.03 +0.10%
Updated February 5 4:02 PM EST. Delayed by at least 15 minutes.

Pfizer Inc up (U.S.)$0.03

Pfizer Inc closed up Friday by (U.S.)$0.03 or 0.10% to (U.S.)$29.03. Over the last five days, shares have lost 4.79% and sit 1.97% above their 52-week low. This security has underperformed the S&P 500 by 3.16% during the last year.

Key company metrics

  • Open(U.S.) $29.02
  • Previous close(U.S.) $29.00
  • High(U.S.) $29.42
  • Low(U.S.) $28.84
  • Bid / Ask(U.S.) $29.01 / (U.S.) $29.03
  • YTD % change-10.07%
  • Volume38,931,172
  • Average volume (10-day)41,779,374
  • Average volume (1-month)34,527,663
  • Average volume (3-month)36,413,632
  • 52-week range(U.S.) $28.47 to (U.S.) $36.46
  • Beta0.89
  • Trailing P/E23.46×
  • P/E 1 year forward12.49×
  • Forward PEG2.30×
  • Indicated annual dividend(U.S.) $1.20
  • Dividend yield4.13%
  • Trailing EPS(U.S.) $1.24
Updated February 5 4:02 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+15.89%

Based on its net profit margin of 15.89%, Pfizer Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 27, 201509/27/2015Jun 28, 201506/28/2015Mar 29, 201503/29/2015Dec 31, 201412/31/2014
Revenue12,08711,85310,86413,118
Total other revenue--------
Total revenue12,08711,85310,86413,118
Gross profit9,8809,6909,03510,433
Total cost of revenue2,2072,1631,8292,685
Total operating expense9,2188,0997,70111,215
Selling / general / administrative3,2703,3863,1043,981
Research & development1,7221,7341,8853,209
Depreciation / amortization937872940949
Interest expense (income), net operating--------
Unusual expense (income)1,286290170531
Other operating expenses, total-204-346-227-140
Operating income2,8693,7543,1631,903
Interest income (expense), net non-operating-278-278-309-353
Gain (loss) on sale of assets351917521
Other--------
Income before tax2,6973,5393,0821,803
Income after tax2,1302,6342,3761,258
Income tax, total567905706545
Net income2,1292,6262,3751,229
Total adjustments to net income100-1
Net income before extra. items2,1212,6252,3701,251
Minority interest-9-9-6-7
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items2,1222,6252,3701,250
Inc. avail. to common incl. extra. items2,1302,6262,3751,228
Diluted net income2,1302,6262,3751,228
Dilution adjustment000--
Diluted weighted average shares6,2436,2436,2926,373
Diluted EPS excluding extraordinary itemsvalue per share0.340.420.380.20
Dividends per sharevalue per share0.280.280.280.26
Diluted normalized EPSvalue per share0.510.460.370.28